BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:With the neurological drug market now worth $86 billion\, and 
 the FDA set to reach a decision on Biogen’s Acudanimib in Spring\, whethe
 r you’re focused on oncology\, Alzheimer’s or ALS\, it’s an exciting time
  to be targeting misfolding diseases. We’ll be bringing together expert r
 esearchers and industry leaders to answer your burning questions\; taking
  a look at the delivery of biologics across the blood brain barrier\, exp
 loring the underlying chemical biology of protein conformation diseases a
 nd hearing what new approaches are emerging to combat misfolding disorder
 s in a variety of therapeutics areas.\n\n\nImprove pre-clinical predictab
 ility by hearing what disease models are now considered best practice wit
 h Beth Hoffman\, Founder and CEO\, Origami Therapeutics and understand ho
 w Pfizer develops physiologically relevant assays for phenotypic screenin
 g\nUnderstand the underlying chemical biology of protein aggregation and 
 the drivers behind misfolding diseases to help inform your target validat
 ion with Peter Lansbury\, CSO\, Lysosomal Therapeutics\nLearn about the l
 atest developments in delivery of biologics across the blood brain barrie
 r as well as viral delivery advancements with Laura Ranum\, Professor\, U
 niversity of Florida\nTarget your aggregate of choice after hearing Behna
 m Nabet\, Research Fellow\, Dana Farber Cancer Institute discuss novel ap
 proaches involving degradation\n
DTEND:20210317T160000
DTSTAMP:20260512T231943Z
DTSTART:20210315T090000
LOCATION:\,
SEQUENCE:0
SUMMARY:With the neurological drug market now worth $86 billion\, and the 
 FDA set to reach a decision on Biogen’s Acudanimib in Spring\, whether yo
 u’re focus...
UID:0135fab3-a56b-449f-8725-879ccf10b31e
END:VEVENT
END:VCALENDAR